abstract |
The present disclosure relates generally to compounds useful in the treatment of conditions involving checkpoint kinases (CHKs), particularly CHK-1 enzymes. In particular, the present invention discloses compounds of formula (IA) which exhibit inhibitory activity on the CHK-1 enzyme. Methods of treating conditions associated with excessive activity of the CHK-1 enzyme with such compounds are disclosed. Also disclosed are their uses, pharmaceutical compositions, kits and synthetic methods. [Formula IA] |